Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small Cajal body-specific RNA 15 (SCARNA15), also known as ACA45, is a small nucleolar RNA localized in Cajal bodies, a subnuclear organelle. SCARNA15 belongs to the H/ACA box class of scaRNAs and primarily guides the pseudouridylation (isomerisation of uridine to pseudouridine) of specific uridine residues in spliceosomal small nuclear RNAs, especially U2 snRNA (notably at position U39)[3][2]. Through directing this RNA modification, SCARNA15 fine-tunes alternative splicing of transcripts involved in chromatin regulation and transcription, impacting the function of key tumor suppressors such as p53 and ATRX[1][2][5]. Loss of SCARNA15 disrupts redox homeostasis, increases sensitivity to oxidative stress, and impairs cancer cell survival and motility, indicating its importance in maintaining stress adaptation and contributing to cancer-associated splicing programs[1][2][5]. SCARNA15 is not a protein, receptor, enzyme, or typical therapeutic target, but rather a regulatory noncoding RNA implicated in post-transcriptional gene regulation and splicing fidelity in both normal and malignant contexts[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small Cajal body-specific RNA 15 (SCARNA15).